Candice R Gurbatri, Georgette A Radford, Laura Vrbanac, Jongwon Im, Elaine M Thomas, Courtney Coker, Samuel R Taylor, YoungUk Jang, Ayelet Sivan, Kyu Rhee, Anas A Saleh, Tiffany Chien, Fereshteh Zandkarimi, Ioana Lia, Tamsin R M Lannagan, Tongtong Wang, Josephine A Wright, Hiroki Kobayashi, Jia Q Ng, Matt Lawrence, Tarik Sammour, Michelle Thomas, Mark Lewis, Lito Papanicolas, Joanne Perry, Tracy Fitzsimmons, Patricia Kaazan, Amanda Lim, Alexandra M Stavropoulos, Dion A Gouskos, Julie Marker, Cheri Ostroff, Geraint Rogers, Nicholas Arpaia, Daniel L Worthley, Susan L Woods, Tal Danino
Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of colorectal adenomas after oral delivery of probiotic E. coli Nissle 1917 (EcN) to a genetically-engineered murine model of CRC predisposition and orthotopic models of CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which CRC patients take either placebo or EcN for two weeks prior to resection of neoplastic and adjacent normal colorectal tissue (ACTRN12619000210178)...
January 20, 2024: Nature Communications